Sun Pharmaceutical’s subsidiary, Sun Pharma Canada Inc, has acknowledged Health Canada’s agreement for ABSORICA LD, an oral drug used to treat severe acne in patients 12 and older.

The approval for the drug comes weeks after the same subsidiary acknowledged a nod from the Canadian drug regulator for WINLEVI, another drug used in severe acne treatment.

The drug’s approval will reinforce Sun Pharma’s dermatology portfolio, a segment in the pharmaceutical market observing strong traction. Dermatology, cardiology, and oncology are sections within the pharma universe that are witnessing vast investments from drug makers to grab the lion’s share.

Sun Pharma also soared on the bandwagon when it acquired US-based Concert Pharmaceuticals for $576 million in January to access the business’s dermatology portfolio. Concert Pharma’s dermatology portfolio comprises experimental drugs for treating skin diseases with patchy hair loss.

Last month, the US Food and Drug Administration (USFDA) also asked Sun Pharma to stop the clinical trials of its experimental dermatological drug amid the potential blood clots.
At 9:29 am, Sun Pharma shares were trading flat at Rs 994.90.